Filing Flows › Evolus (EOLS) › Guidance & outlook
Evolus (EOLS) guidance and outlook
Evolus (EOLS) lowered its guidance on Nov 4, 2026: Revenue $330M–$337M for FY2026; Gross margin 67%–67.5% for FY2026; EBITDA margin 13%–15% for FY2028; Revenue +11% to +13% for FY2026. Evolus' 10-Q filed Nov 4, 2026 makes 26 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $330M–$337M | reaffirmed |
| Gross margin | FY2026 | 67%–67.5% | reaffirmed |
| Revenue | long-term | $450M–$500M | reaffirmed |
| Revenue | long-term | +15% to +19% | reaffirmed |
| EBITDA margin | FY2028 | 13%–15% | reaffirmed |
| Revenue | FY2026 | +11% to +13% | reaffirmed |
| Operating expenses | FY2026 | $210M–$213M | lowered |
| Operating expenses | FY2026 | 0% to +2% | lowered |
| Revenue | long-term | $450M–$500M | reaffirmed |
| Revenue | long-term | +15% to +19% | reaffirmed |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- We anticipate two additional Evolysse ® products, Evolysse ® Sculpt and Evolysse ® Lips, to be approved in the United States in 2026 and 2027, respectively.
- We anticipate commercialization of Profhilo ® in the United States in 2030, subject to regulatory approval.
- We anticipate commercialization in these new territories in 2028, subject to applicable regulatory approvals.
- Tariffs applicable to our products will increase our costs and, absent mitigation, adversely affect our gross margin and operating results.
- Following additional Commerce guidance issued in September 2026, we currently do not expect Jeuveau® to be subject to such tariffs.
- Revenues are recognized when the control of the promised goods is transferred to the customer in an amount that reflects the consideration allocated to the related performance obligations and to which we expect to be entitled in exchange for those products or services.
- We anticipate our continued sales growth will depend on (i) our ability to grow our customer base and to increase purchases by our current customers in the competitive aesthetic market, (ii) the continued success of Evolysse ® Form and Evolysse ® Smooth products in the United States, (iii) the success of the commercial launch of Evolysse ® injectable HA gel collection in Europe and (iv) the regulatory approval…
- We anticipate that our cost of goods sold will fluctuate due to changes in product and geographic mix and the impact of current and threatened tariffs.
- We anticipate that our gross profit margin will fluctuate due to changes in product and geographic mix, the effect of current and threatened tariffs, and the impact of promotional and incentive programs on our average selling prices.
- We expect our research and development expenses to increase, if and when, we develop additional product candidates and pursue regulatory approvals.
- Changes to the fair value of the contingent royalty obligation payable to Evolus Founders are driven by changes in management assumptions relating to revenue forecasts, the discount rate used and the timing of cash flows.
- Interest on the Revolving Credit Facility and the New Pharmakon Term Loans (as defined below) is based on variable interest rates, which we expect will continue to fluctuate with
Evolus' latest quarter
Evolus, Q3 2026: revenue $78.0M (+13% year over year), operating margin -10.8%, net loss $12.5M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
Questions
Did Evolus raise or lower its guidance?
Evolus (EOLS) lowered its guidance on Nov 4, 2026: Revenue $330M–$337M for FY2026; Gross margin 67%–67.5% for FY2026; EBITDA margin 13%–15% for FY2028; Revenue +11% to +13% for FY2026.
What does Evolus expect?
We anticipate two additional Evolysse ® products, Evolysse ® Sculpt and Evolysse ® Lips, to be approved in the United States in 2026 and 2027, respectively. We anticipate commercialization of Profhilo ® in the United States in 2030, subject to regulatory approval. We anticipate commercialization in these new territories in 2028, subject to applicable regulatory approvals.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.